Neurotoxicity of Methamphetamine and 3,4-methylenedioxymethamphetamine

Overview

Journal Life Sci

Publisher Elsevier

Specialties Biochemistry
Biology
Physiology

Date 2013 Jul 30

PMID 23892199

Citations 89

Authors

Laura E Halpin

Stuart A Collins

Bryan K Yamamoto

Affiliations

Soon will be listed here.

Abstract

Amphetamines are a class of psychostimulant drugs that are widely abused for their stimulant, euphoric, empathogenic and hallucinogenic properties. Many of these effects result from acute increases in dopamine and serotonin neurotransmission. Subsequent to these acute effects, methamphetamine and 3,4 methylenedioxymethamphetamine (MDMA) produce persistent damage to dopamine and serotonin nerve terminals. This review summarizes the numerous interdependent mechanisms including excitotoxicity, mitochondrial damage and oxidative stress that have been demonstrated to contribute to this damage. Emerging non-neuronal mechanisms by which the drugs may contribute to monoaminergic terminal damage, as well as the neuropsychiatric consequences of this terminal damage are also presented. Methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA) have similar chemical structures and pharmacologic properties compared to other abused substances including cathinone (khat), as well as a relatively new class of novel synthetic amphetamines known as 'bath salts' that have gained popularity among drug abusers.

Citing Articles

Genes, Cognition, and Their Interplay in Methamphetamine Use Disorder.

Khan R, Turner A, Berk M, Walder K, Rossell S, Guerin A Biomolecules. 2025; 15(2).

PMID: 40001609 PMC: 11852989. DOI: 10.3390/biom15020306.

Recent advances in nanotherapeutics for HIV-associated neurocognitive disorders and substance use disorders.

Lomas C, Dubey R, Perez-Alvarez G, Lopez Hernandez Y, Atmar A, Arias A Nanomedicine (Lond). 2025; 20(6):603-619.

PMID: 39963928 PMC: 11902879. DOI: 10.1080/17435889.2025.2461984.

Molecular Mechanisms of Methamphetamine-Induced Addiction via TAAR1 Activation.

Lin Y, Wang J, Shi F, Yang L, Wu S, Qiao A J Med Chem. 2024; 67(20):18593-18605.

PMID: 39358311 PMC: 11513891. DOI: 10.1021/acs.jmedchem.4c01961.

Synthetic Cathinones: Epidemiology, Toxicity, Potential for Abuse, and Current Public Health Perspective.

Chen S, Zhou W, Lai M Brain Sci. 2024; 14(4).

PMID: 38671986 PMC: 11048581. DOI: 10.3390/brainsci14040334.

Modeling methamphetamine use disorder in mammals: Sex differences in behavioral, biochemical, and transcriptional consequences.

Daiwile A, Cadet J Adv Pharmacol. 2024; 99:145-168.

PMID: 38467480 PMC: 11474929. DOI: 10.1016/bs.apha.2023.08.002.

References

Zhu J, Xu W, Angulo N, Angulo J . Methamphetamine-induced striatal apoptosis in the mouse brain: comparison of a binge to an acute bolus drug administration. Neurotoxicology. 2005; 27(1):131-6. PMC: 2896282. DOI: 10.1016/j.neuro.2005.05.014. View

Eyerman D, Yamamoto B . A rapid oxidation and persistent decrease in the vesicular monoamine transporter 2 after methamphetamine. J Neurochem. 2007; 103(3):1219-27. DOI: 10.1111/j.1471-4159.2007.04837.x. View

Hermens D, Lubman D, Ward P, Naismith S, Hickie I . Amphetamine psychosis: a model for studying the onset and course of psychosis. Med J Aust. 2009; 190(S4):S22-5. DOI: 10.5694/j.1326-5377.2009.tb02370.x. View

Kuhn D, Francescutti-Verbeem D, Thomas D . Dopamine quinones activate microglia and induce a neurotoxic gene expression profile: relationship to methamphetamine-induced nerve ending damage. Ann N Y Acad Sci. 2006; 1074:31-41. DOI: 10.1196/annals.1369.003. View

Cameron K, Kolanos R, Solis Jr E, Glennon R, De Felice L . Bath salts components mephedrone and methylenedioxypyrovalerone (MDPV) act synergistically at the human dopamine transporter. Br J Pharmacol. 2012; 168(7):1750-7. PMC: 3605880. DOI: 10.1111/bph.12061. View

Anneken J, Gudelsky G . MDMA produces a delayed and sustained increase in the extracellular concentration of glutamate in the rat hippocampus. Neuropharmacology. 2012; 63(6):1022-7. PMC: 3437747. DOI: 10.1016/j.neuropharm.2012.07.026. View

Bruno V, Scapagnini U, Canonico P . Excitatory amino acids and neurotoxicity. Funct Neurol. 1993; 8(4):279-92. View

Potash M, Gordon K, Conrad K . Persistent Psychosis and Medical Complications After a Single Ingestion of MDMA "Ecstasy": A Case Report and Review of the Literature. Psychiatry (Edgmont). 2009; 6(7):40-4. PMC: 2728937. View

Patel A, Moreland T, Haq F, Siddiqui F, Mikul M, Qadir H . Persistent Psychosis After a Single Ingestion of "Ecstasy" (MDMA). Prim Care Companion CNS Disord. 2012; 13(6). PMC: 3304680. DOI: 10.4088/PCC.11l01200. View

10.

Do J, Schenk S . Self-administered MDMA produces dose- and time-dependent serotonin deficits in the rat brain. Addict Biol. 2011; 18(3):441-7. DOI: 10.1111/j.1369-1600.2011.00370.x. View

11.

Krystal J, Price L, Opsahl C, Ricaurte G, Heninger G . Chronic 3,4-methylenedioxymethamphetamine (MDMA) use: effects on mood and neuropsychological function?. Am J Drug Alcohol Abuse. 1992; 18(3):331-41. DOI: 10.3109/00952999209026070. View

12.

Puffenbarger R, Boothe A, Cabral G . Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells. Glia. 1999; 29(1):58-69. View

13.

Morgan M . Recreational use of "ecstasy" (MDMA) is associated with elevated impulsivity. Neuropsychopharmacology. 1998; 19(4):252-64. DOI: 10.1016/S0893-133X(98)00012-8. View

14.

Thomas D, Walker P, Benjamins J, Geddes T, Kuhn D . Methamphetamine neurotoxicity in dopamine nerve endings of the striatum is associated with microglial activation. J Pharmacol Exp Ther. 2004; 311(1):1-7. DOI: 10.1124/jpet.104.070961. View

15.

Escubedo E, Guitart L, Sureda F, Jimenez A, Pubill D, Pallas M . Microgliosis and down-regulation of adenosine transporter induced by methamphetamine in rats. Brain Res. 1998; 814(1-2):120-6. DOI: 10.1016/s0006-8993(98)01065-8. View

16.

Hadlock G, Webb K, McFadden L, Chu P, Ellis J, Allen S . 4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse. J Pharmacol Exp Ther. 2011; 339(2):530-6. PMC: 3200001. DOI: 10.1124/jpet.111.184119. View

17.

OHearn E, Battaglia G, DE SOUZA E, Kuhar M, Molliver M . Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J Neurosci. 1988; 8(8):2788-803. PMC: 6569396. View

18.

Milroy C, Clark J, FORREST A . Pathology of deaths associated with "ecstasy" and "eve" misuse. J Clin Pathol. 1996; 49(2):149-53. PMC: 500349. DOI: 10.1136/jcp.49.2.149. View

19.

Wang G, Smith L, Volkow N, Telang F, Logan J, Tomasi D . Decreased dopamine activity predicts relapse in methamphetamine abusers. Mol Psychiatry. 2011; 17(9):918-25. PMC: 3261322. DOI: 10.1038/mp.2011.86. View

20.

Mizoguchi H, Arai S, Koike H, Ibi D, Kamei H, Nabeshima T . Therapeutic potential of nicotine for methamphetamine-induced impairment of sensorimotor gating: involvement of pallidotegmental neurons. Psychopharmacology (Berl). 2009; 207(2):235-43. DOI: 10.1007/s00213-009-1651-z. View